Navigation Links
Groundbreaking Study Proves Personalized Diet Based on Genetics Leads to Significant Advances in Long Term Weight Management and Blood Glucose Levels
Date:10/22/2007

0 mg/dl, 57% of the nutrigenetic group, compared to only 25% of the control group had levels reduced to less that 100 mg/dl after more than 90 days of weight management therapy. These results reflected a return to normal blood glucose levels from pre-diabetic levels in the nutrigenetic group, based on a genetically tailored diet and exercise program.

Sciona's Chief Science Officer, Dr. Rosalynn Gill stated, "We are delighted with the results of this study given the global health problems associated with clinical obesity and diabetes." Dr. Gill went on to note that according to the US Department of Health and Human Services, the total cost of obesity, including those illnesses associated with obesity such as type II diabetes, coronary heart disease, and hypertension in the year 2000 was approximately $117 billion dollars. Sciona's CEO, Peter Vitulli, stated, "Sciona's Mycellf genetic testing kit allows an individual to learn how to personalize their nutrition and lifestyle to match their genes, which gives them a revolutionary gene-based road map to better health and a longer life." Study coordinator, Dr. Ioannis Arkadianos, stated, "The results of this clinical study featuring the application of nutrigenetics clearly demonstrates that using genetic information is critical in helping people optimize their health. As a clinician, it is gratifying to be able to apply the information regarding an individual's inherited genetic code to help us to understand how each person's body works. We finally have the tools that enable health care professionals such as myself to determine which nutrition and exercise protocols will get results and what nutrigenetic interventions will promote longevity. Just like fingerprints, no two individuals are the same and so we are now able to personalize your health based on your DNA."

Summary: Tailoring a weight loss program to individuals' unique genetic profiles, even in a group with a history of prior weight loss failures, res
'/>"/>

SOURCE Sciona, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:AMP Receives $1.4 Million Grant From the Bill & Melinda Gates Foundation to Improve Advocacy for VACCINES and Immunization Systems in West Africa 2AMP Receives $1.4 Million Grant From the Bill & Melinda Gates Foundation to Improve Advocacy for VACCINES and Immunization Systems in West Africa 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Elsevier Selects BrainTrack Directory as Supplier of College Data 2Elsevier Selects BrainTrack Directory as Supplier of College Data 3Elsevier Selects BrainTrack Directory as Supplier of College Data 4Protecting humans and animals from diseases in wildlife 10285 1Protecting humans and animals from diseases in wildlife 10285 2New Singapore France research alliance to develop state of the art nanotechnologies 10281 1New Singapore France research alliance to develop state of the art nanotechnologies 10281 2New Singapore France research alliance to develop state of the art nanotechnologies 10281 3MedicAlert Foundation International and CAP STS Collaborate to Standardize Emergency Medical Information 59051 1MedicAlert Foundation International and CAP STS Collaborate to Standardize Emergency Medical Information 59051 2MedicAlert Foundation International and CAP STS Collaborate to Standardize Emergency Medical Information 59051 3MedicAlert Foundation International and CAP STS Collaborate to Standardize Emergency Medical Information 59051 4